Skip to Main Content

Paper Details

Characterizing Treatment Non-responders vs. Responders in Completed Alzheimer's Disease Clinical Trials.
medRxiv
0
2023
AD, Alzheimer's Disease, Alzheimer's disease, Bapineuzumab, Galantamine, Semagacestat, dementia, patient, patients
Author NameAffiliation
Dulin WangThe University of Texas Health Center at Houston
Yaobin LingThe University of Texas Health Center at Houston
Kristofer HarrisMcGovern Medical School, The University of Texas Health Science Center at Houston
Paul E SchulzMcGovern Medical School, The University of Texas Health Science Center at Houston
Xiaoqian JiangThe University of Texas Health Center at Houston
Yejin KimThe University of Texas Health Center at Houston
  • 1 - 6

Datasets